Institutional Investors Lead Shift in Newlink Genetics Corp (NASDAQ:NLNK) Sentiment

NewLink Genetics Corporation (NASDAQ:NLNK) Logo

Sentiment for Newlink Genetics Corp (NASDAQ:NLNK)

Newlink Genetics Corp (NASDAQ:NLNK) institutional sentiment increased to 0.97 in 2018 Q4. Its up 0.28, from 0.69 in 2018Q3. The ratio improved, as 31 investment managers increased or started new positions, while 32 cut down and sold stakes in Newlink Genetics Corp. The investment managers in our partner’s database reported: 12.64 million shares, down from 13.36 million shares in 2018Q3. Also, the number of investment managers holding Newlink Genetics Corp in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 12 Reduced: 20 Increased: 15 New Position: 16.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $71.20 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. It currently has negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.

The stock increased 7.30% or $0.13 during the last trading session, reaching $1.91. About 907,929 shares traded or 112.61% up from the average. NewLink Genetics Corporation (NASDAQ:NLNK) has declined 74.11% since March 17, 2018 and is downtrending. It has underperformed by 78.48% the S&P500.

Analysts await NewLink Genetics Corporation (NASDAQ:NLNK) to report earnings on May, 2. They expect $-0.30 EPS, up 38.78 % or $0.19 from last year’s $-0.49 per share. After $-0.28 actual EPS reported by NewLink Genetics Corporation for the previous quarter, Wall Street now forecasts 7.14 % negative EPS growth.

Anson Funds Management Lp holds 0.25% of its portfolio in NewLink Genetics Corporation for 282,262 shares. Bogle Investment Management L P De owns 52,324 shares or 0.01% of their US portfolio. Moreover, Connor Clark & Lunn Investment Management Ltd. has 0.01% invested in the company for 633,597 shares. The New York-based A.R.T. Advisors Llc has invested 0% in the stock. Acadian Asset Management Llc, a Massachusetts-based fund reported 321,504 shares.

NewLink Genetics Corporation (NASDAQ:NLNK) Ratings Coverage

Ratings analysis reveals 0 of NewLink Genetics’s analysts are positive. Out of 2 Wall Street analysts rating NewLink Genetics, 0 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $4 while the high is $5. The stock’s average target of $4.50 is 135.60% above today’s ($1.91) share price. NLNK was included in 4 notes of analysts from November 2, 2018. The stock of NewLink Genetics Corporation (NASDAQ:NLNK) has “Neutral” rating given on Friday, November 2 by Bank of America. Robert W. Baird maintained the stock with “Neutral” rating in Thursday, February 28 report. The rating was downgraded by Bank of America to “Underperform” on Thursday, January 3.

More notable recent NewLink Genetics Corporation (NASDAQ:NLNK) news were published by: Seekingalpha.com which released: “NewLink Genetics: Explicating The Changing Fundamentals Of A Potential Comeback – Seeking Alpha” on May 17, 2018, also Businesswire.com with their article: “NewLink Genetics Announces Final Results from Two Phase 2 Studies of Indoximod Presented at ASCO 2018 – Business Wire” published on June 04, 2018, Benzinga.com published: “The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO – Benzinga” on December 28, 2018. More interesting news about NewLink Genetics Corporation (NASDAQ:NLNK) were released by: Globenewswire.com and their article: “NewLink Genetics Appoints Chad A. Johnson to Board of Directors – GlobeNewswire” published on March 21, 2018 as well as Seekingalpha.com‘s news article titled: “IDO Is Still A Valid Pathway For NewLink Genetics – Seeking Alpha” with publication date: November 08, 2018.

NewLink Genetics Corporation (NASDAQ:NLNK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.